Tuesday, May 6, 2025

6:30 PM to 9:00 PM Eastern Time
 
Myeloma CME/CE Rounds Philadelphia
DoubleTree by Hilton Philadelphia Center City
Symphony Ballroom 
237 South Broad Street 
Philadelphia, PA 19107
 
LLS will cover self-parking at the DoubleTree for practicing healthcare professionals, upon completion of your pre/post assessment, evaluation, and feedback form.
 
*Only one (1) person per medical technology/pharmaceutical company may register and attend the Rounds. A corporate email address is required.

Agenda

6:30 PM – Dinner and Networking
7:00 PM – Welcome and Overview of Program
Edward A. Stadtmauer
7:05 PM – Overview of LLS Resources
Ruby Nava-Ramos
7:15 PM – Case Presentation and Discussion on Unusual Complications with Bispecific Treatments, CNS Toxoplasmosis, CMV Activation, PML
Anil K. Rengan and Jessica Rais
7:45 PM –  Case Presentation and Discussion on Treatment of Smoldering Myeloma
Adam Waxman and Daria Madeeva
8:15 PM – Case Presentation and Discussion on Newly Diagnosed Myeloma: How, When, and If We Should Consolidate with Autologous Stem Cell Transplant
Adam Binder and Tara Rakiewicz
8:45 PM – Discussion and Wrap-up
All Faculty
9:00 PM – Conclusion
Edward A. Stadtmauer
 

Description

Live interactive continuing medical education activity for healthcare professionals in Philadelphia, New Jersey, Delaware, and surrounding areas to discuss myeloma updates and challenges in treatment.

Target Audience

This activity is intended for hematologists-oncologists, medical oncologists, physician associates, advanced practice providers, nurses and pharmacists involved in the care of patients with myeloma.

Educational Objectives

After completing this activity, the participant should be better able to:
  • Describe the latest developments in myeloma, including current and emerging treatments
  • Engage patients and caregivers in clinical trials discussions on newly approved and emerging therapies for myeloma, including combination therapies, CAR T-cell therapy and bispecific antibodies
  • Explain disparities and challengies in diagnosis and treatment of myeloma
  • Apply evidence-based treatment strategies for optimal patient care
  • Identify patient education and support resources

Advisory Group

Edward A. Stadtmauer, MD (Chair) 
University of Pennsylvania
Abramson Cancer Center 
Philadelphia, PA 
 
Adam Binder, MD 
Thomas Jefferson University Hospital 
Philadelphia, PA 
 
Tulin Budak-Alpdogan, MD 
Cooper University Health Care 
Camden, NJ
 
Oxana Megherea, PharmD, BCOP
University of Pennsylvania
Abramson Cancer Center
Philadelphia, PA
 
Asya Varshavsky-Yanovsky, MD, PhD 
Temple University Health System 
Fox Chase Cancer Center 
Philadelphia, PA
 
Adam Waxman, MD, MS 
University of Pennsylvania 
Abramson Cancer Center 
Philadelphia, PA

Faculty

Edward A. Stadtmauer, MD (Chair) 
University of Pennsylvania
Abramson Cancer Center 
Philadelphia, PA
 
Adam Binder, MD 
Thomas Jefferson University Hospital 
Philadelphia, PA 
 
Daria Madeeva, MD
University of Pennsylvania 
Abramson Cancer Center 
Philadelphia, PA
 
Ruby Nava-Ramos, MPH
The Leukemia & Lymphoma Society
Washington, DC
 
Jessica Rais, MD
Cooper University Health Care 
Camden, NJ
 
Tara Rakiewicz, MD
Thomas Jefferson University Hospital 
Philadelphia, PA
 
Anil K. Rengan, MD 
Cooper University Health Care 
Camden, NJ
 
Adam Waxman, MD, MS 
University of Pennsylvania 
Abramson Cancer Center 
Philadelphia, PA
 
This activity is provided by The Leukemia & Lymphoma Society and Medical Learning Institute Inc, in collaboration with the Association of Cancer Care Centers™ (ACCC).
 
 

Supported by educational grants from Adaptive Biotechnologies Corporation and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

 

For questions, concerns, or assistance for people with disabilities or grievances, please contact us at: Profeducation@LLS.org.

 

Follow LLS